AC Immune SA
NASDAQ:ACIU
Intrinsic Value
AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. [ Read More ]
The intrinsic value of one ACIU stock under the Base Case scenario is 9.29 USD. Compared to the current market price of 2.96 USD, AC Immune SA is Undervalued by 68%.
Valuation Backtest
AC Immune SA
Run backtest to discover the historical profit from buying and selling ACIU stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of AC Immune SA's business.
What risks and challenges
does AC Immune SA face in the near future?
Summarize the latest earnings report
of AC Immune SA.
Provide P/E
for AC Immune SA and its competitors.
Balance Sheet Decomposition
AC Immune SA
Current Assets | 125.2m |
Cash & Short-Term Investments | 103m |
Receivables | 15.7m |
Other Current Assets | 6.4m |
Non-Current Assets | 57.7m |
Long-Term Investments | 361k |
PP&E | 6.9m |
Intangibles | 50.4m |
Current Liabilities | 13.6m |
Accounts Payable | 1.7m |
Accrued Liabilities | 11.1m |
Other Current Liabilities | 810k |
Non-Current Liabilities | 8.6m |
Long-Term Debt | 2.8m |
Other Non-Current Liabilities | 5.8m |
Earnings Waterfall
AC Immune SA
Revenue
|
14.8m
CHF
|
Operating Expenses
|
-68.4m
CHF
|
Operating Income
|
-53.6m
CHF
|
Other Expenses
|
-609k
CHF
|
Net Income
|
-54.2m
CHF
|
Free Cash Flow Analysis
AC Immune SA
What is Free Cash Flow?
ACIU Profitability Score
Profitability Due Diligence
AC Immune SA's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
AC Immune SA's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
ACIU Solvency Score
Solvency Due Diligence
AC Immune SA's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
AC Immune SA's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ACIU Price Targets Summary
AC Immune SA
According to Wall Street analysts, the average 1-year price target for ACIU is 10.71 USD with a low forecast of 6.57 USD and a high forecast of 16.8 USD.
Shareholder Return
ACIU Price
AC Immune SA
Average Annual Return | -6.82% |
Standard Deviation of Annual Returns | 56.83% |
Max Drawdown | -83% |
Market Capitalization | 293.6m USD |
Shares Outstanding | 99 197 800 |
Percentage of Shares Shorted | 1.03% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 143 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Contact
IPO
Employees
Officers
The intrinsic value of one ACIU stock under the Base Case scenario is 9.29 USD.
Compared to the current market price of 2.96 USD, AC Immune SA is Undervalued by 68%.